• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

犬源和人源凝血因子VIII在基因递送中的生物学差异评估:对人类血友病治疗的意义。

Evaluation of the biological differences of canine and human factor VIII in gene delivery: implications in human hemophilia treatment.

作者信息

Wang Q, Dong B, Firrman J, Wu W, Roberts S, Moore A R, Liu L S, Chin M P S, Diao Y, Kost J, Xiao W

机构信息

School of Biomedical Sciences, Huaqiao University, Quanzhou, Fujian, China.

Sol Sherry Thrombosis Research Center, Temple University, Philadelphia, PA, USA.

出版信息

Gene Ther. 2016 Jul;23(7):597-605. doi: 10.1038/gt.2016.34. Epub 2016 Apr 11.

DOI:10.1038/gt.2016.34
PMID:27064790
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4936945/
Abstract

The canine is the most important large animal model for testing novel hemophilia A (HA) treatment. It is often necessary to use canine factor VIII (cFIII) gene or protein for the evaluation of HA treatment in the canine model. However, different biological properties between cFVIII and human FVIII (hFVIII) indicated that the development of novel HA treatment may require careful characterization of non-human FVIII. To investigate whether the data obtained using cFVIII can translate to HA treatment in human, we analyzed the differential biological properties of canine heavy chain (cHC) and light chain (cLC) by comparing with human heavy chain (hHC) and light chain (hLC). The secretion of cHC was 5-30-fold higher than hHC, with or without light chains (LCs). cHC+hLC group exhibited ~18-fold increase in coagulation activity compared with hHC+hLC delivery by recombinant adeno-associated viral vectors. Unlike hHC, the secretion of cHC was independent of LCs. cLC improves the specific activity of FVIII by two- to threefold compared with hLC. Moreover, the cLC, but not cHC, contributes to the higher stability of cFVIII. Our results suggested that the cFVIII expression results in the canine model should be interpreted with caution as the cHC secreted more efficiently than hHC and cLC exhibited a more active and stable phenotype than hLC.

摘要

犬类是测试新型血友病A(HA)治疗方法的最重要的大型动物模型。在犬类模型中评估HA治疗方法时,通常需要使用犬类因子VIII(cFIII)基因或蛋白质。然而,cFVIII与人类FVIII(hFVIII)之间不同的生物学特性表明,新型HA治疗方法的开发可能需要仔细表征非人类FVIII。为了研究使用cFVIII获得的数据是否可以转化为人类的HA治疗,我们通过与人类重链(hHC)和轻链(hLC)比较,分析了犬类重链(cHC)和轻链(cLC)的差异生物学特性。无论有无轻链(LC),cHC的分泌都比hHC高5至30倍。与通过重组腺相关病毒载体递送hHC+hLC相比,cHC+hLC组的凝血活性提高了约18倍。与hHC不同,cHC的分泌不依赖于LC。与hLC相比,cLC使FVIII的比活性提高了两到三倍。此外,cLC而非cHC有助于提高cFVIII的稳定性。我们的结果表明,由于cHC的分泌效率高于hHC,且cLC表现出比hLC更活跃和稳定的表型,因此在犬类模型中cFVIII表达的结果应谨慎解读。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2e6f/4936945/01bc1dffce71/nihms771785f8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2e6f/4936945/4a7f45166092/nihms771785f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2e6f/4936945/d8f79bf906ad/nihms771785f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2e6f/4936945/85edffe2687b/nihms771785f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2e6f/4936945/5083022ea6c7/nihms771785f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2e6f/4936945/15a89fc091ca/nihms771785f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2e6f/4936945/7d05fc0db7e4/nihms771785f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2e6f/4936945/b46ee9b6741d/nihms771785f7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2e6f/4936945/01bc1dffce71/nihms771785f8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2e6f/4936945/4a7f45166092/nihms771785f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2e6f/4936945/d8f79bf906ad/nihms771785f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2e6f/4936945/85edffe2687b/nihms771785f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2e6f/4936945/5083022ea6c7/nihms771785f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2e6f/4936945/15a89fc091ca/nihms771785f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2e6f/4936945/7d05fc0db7e4/nihms771785f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2e6f/4936945/b46ee9b6741d/nihms771785f7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2e6f/4936945/01bc1dffce71/nihms771785f8.jpg

相似文献

1
Evaluation of the biological differences of canine and human factor VIII in gene delivery: implications in human hemophilia treatment.犬源和人源凝血因子VIII在基因递送中的生物学差异评估:对人类血友病治疗的意义。
Gene Ther. 2016 Jul;23(7):597-605. doi: 10.1038/gt.2016.34. Epub 2016 Apr 11.
2
Long-term correction of hemorrhagic diathesis in hemophilia A mice by an AAV-delivered hybrid FVIII composed of the human heavy chain and the rat light chain.腺相关病毒载体递送的人重链-鼠轻链杂交凝血因子 VIII 长期纠正血友病 A 小鼠的出血倾向。
Front Med. 2022 Aug;16(4):584-595. doi: 10.1007/s11684-021-0844-7. Epub 2022 Jan 17.
3
Efficacy and safety of long-term prophylaxis in severe hemophilia A dogs following liver gene therapy using AAV vectors.AAV 载体肝基因治疗重度 A 型血友病犬的长期预防的疗效和安全性。
Mol Ther. 2011 Mar;19(3):442-9. doi: 10.1038/mt.2010.240. Epub 2010 Nov 16.
4
Helper-dependent adenoviral vectors mediate therapeutic factor VIII expression for several months with minimal accompanying toxicity in a canine model of severe hemophilia A.在严重血友病A犬模型中,辅助依赖型腺病毒载体介导治疗性因子VIII表达数月,且伴随的毒性极小。
Blood. 2004 Feb 1;103(3):804-10. doi: 10.1182/blood-2003-05-1426. Epub 2003 Sep 25.
5
Novel factor VIII variants with a modified furin cleavage site improve the efficacy of gene therapy for hemophilia A.具有修饰的弗林蛋白酶切割位点的新型凝血因子 VIII 变体可提高A型血友病基因治疗的疗效。
J Thromb Haemost. 2017 Jan;15(1):110-121. doi: 10.1111/jth.13543. Epub 2016 Nov 25.
6
Liver-restricted expression of the canine factor VIII gene facilitates prevention of inhibitor formation in factor VIII-deficient mice.肝脏特异性表达犬凝血因子 VIII 基因可促进预防凝血因子 VIII 缺乏症小鼠产生抑制物。
J Gene Med. 2009 Nov;11(11):1020-9. doi: 10.1002/jgm.1391.
7
In vivo evaluation of an adenoviral vector encoding canine factor VIII: high-level, sustained expression in hemophiliac mice.编码犬因子VIII的腺病毒载体的体内评估:在血友病小鼠中的高水平持续表达。
Hum Gene Ther. 1999 Jul 20;10(11):1791-802. doi: 10.1089/10430349950017473.
8
Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs.腺相关病毒2型、6型和8型向血友病A小鼠和犬递送凝血因子VIII的多年治疗益处。
Blood. 2006 Jul 1;108(1):107-15. doi: 10.1182/blood-2005-12-5115. Epub 2006 Mar 7.
9
Phenotype correction of hemophilia A mice with adeno-associated virus vectors carrying the B domain-deleted canine factor VIII gene.携带缺失B结构域的犬因子VIII基因的腺相关病毒载体对血友病A小鼠进行表型校正
Thromb Res. 2006;118(5):627-35. doi: 10.1016/j.thromres.2005.11.006. Epub 2005 Dec 20.
10
Heterogeneity of the immune response to adenovirus-mediated factor VIII gene therapy in different inbred hemophilic mouse strains.不同近交系血友病小鼠品系对腺病毒介导的因子VIII基因治疗的免疫反应异质性。
J Gene Med. 2004 Dec;6(12):1358-68. doi: 10.1002/jgm.624.

引用本文的文献

1
RNAi targeting heparin cofactor II promotes hemostasis in a canine model of acquired hemophilia A.靶向肝素辅因子II的RNA干扰在获得性血友病A犬模型中促进止血。
Gene Ther. 2025 May 24. doi: 10.1038/s41434-025-00541-w.
2
Genomic Designs of rAAVs Contribute to Pathological Changes in the Livers and Spleens of Mice.重组腺相关病毒的基因组设计导致小鼠肝脏和脾脏的病理变化。
Adv Cell Gene Ther. 2022;2022. doi: 10.1155/2022/6807904. Epub 2022 Mar 20.
3
Adding recombinant AAVs to the cancer therapeutics mix.将重组腺相关病毒添加到癌症治疗组合中。

本文引用的文献

1
Progress and challenges in the development of a cell-based therapy for hemophilia A.A型血友病细胞疗法开发中的进展与挑战。
J Thromb Haemost. 2014 Dec;12(12):1954-65. doi: 10.1111/jth.12750. Epub 2014 Oct 31.
2
Efficient production of dual recombinant adeno-associated viral vectors for factor VIII delivery.用于递送凝血因子VIII的双重组腺相关病毒载体的高效生产。
Hum Gene Ther Methods. 2014 Aug;25(4):261-8. doi: 10.1089/hgtb.2014.093.
3
Current status of haemophilia gene therapy.血友病基因治疗的现状。
Mol Ther Oncolytics. 2022 Oct 2;27:73-88. doi: 10.1016/j.omto.2022.09.009. eCollection 2022 Dec 15.
4
Long-term correction of hemorrhagic diathesis in hemophilia A mice by an AAV-delivered hybrid FVIII composed of the human heavy chain and the rat light chain.腺相关病毒载体递送的人重链-鼠轻链杂交凝血因子 VIII 长期纠正血友病 A 小鼠的出血倾向。
Front Med. 2022 Aug;16(4):584-595. doi: 10.1007/s11684-021-0844-7. Epub 2022 Jan 17.
5
Enhancing therapeutic efficacy of in vivo platelet-targeted gene therapy in hemophilia A mice.增强体内血小板靶向基因治疗血友病 A 小鼠的疗效。
Blood Adv. 2020 Nov 24;4(22):5722-5734. doi: 10.1182/bloodadvances.2020002479.
6
B Cell Depletion Eliminates FVIII Memory B Cells and Enhances AAV8-coF8 Immune Tolerance Induction When Combined With Rapamycin.B 细胞耗竭消除 FVIII 记忆 B 细胞,并与雷帕霉素联合增强 AAV8-coF8 免疫耐受诱导。
Front Immunol. 2020 Jun 24;11:1293. doi: 10.3389/fimmu.2020.01293. eCollection 2020.
7
Identification of Key Coagulation Activity Determining Elements in Canine Factor VIII.犬因子VIII中关键凝血活性决定因素的鉴定
Mol Ther Methods Clin Dev. 2020 Jan 15;17:328-336. doi: 10.1016/j.omtm.2019.12.019. eCollection 2020 Jun 12.
8
Evaluation of the activity levels of rat FVIII and human FVIII delivered by adeno-associated viral vectors both in vitro and in vivo.评估腺相关病毒载体递送的大鼠FVIII和人FVIII在体外和体内的活性水平。
Blood Cells Mol Dis. 2018 Nov;73:47-54. doi: 10.1016/j.bcmd.2018.09.004. Epub 2018 Sep 20.
Haemophilia. 2014 May;20 Suppl 4:43-9. doi: 10.1111/hae.12411.
4
Factor VIII therapy for hemophilia A: current and future issues.因子 VIII 治疗 A 型血友病:当前和未来的问题。
Expert Rev Hematol. 2014 Jun;7(3):373-85. doi: 10.1586/17474086.2014.899896. Epub 2014 Apr 10.
5
Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant.单次外周静脉给予编码新型人凝血因子 VIII 变体的 rAAV 载体后 FVIII 的治疗水平。
Blood. 2013 Apr 25;121(17):3335-44. doi: 10.1182/blood-2012-10-462200. Epub 2013 Feb 20.
6
Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A.增强重组因子 VIII 的药代动力学特性:在血友病 A 患者中进行的糖基化 PEG 化重组因子 VIII 的首次人体试验。
J Thromb Haemost. 2013 Apr;11(4):670-8. doi: 10.1111/jth.12161.
7
Minimal modification in the factor VIII B-domain sequence ameliorates the murine hemophilia A phenotype.VIII 因子 B 结构域序列的微小修饰可改善小鼠血友病 A 表型。
Blood. 2013 May 23;121(21):4396-403. doi: 10.1182/blood-2012-10-464164. Epub 2013 Jan 31.
8
Factor VIII products and inhibitor development in severe hemophilia A.VIII 因子产品与严重甲型血友病抑制物的产生。
N Engl J Med. 2013 Jan 17;368(3):231-9. doi: 10.1056/NEJMoa1208024.
9
The gene therapy journey for hemophilia: are we there yet?基因治疗血友病之旅:我们到了吗?
Hematology Am Soc Hematol Educ Program. 2012;2012:375-81. doi: 10.1182/asheducation-2012.1.375.
10
Development and characterization of recombinant ovine coagulation factor VIII.重组绵羊凝血因子 VIII 的开发和特性研究。
PLoS One. 2012;7(11):e49481. doi: 10.1371/journal.pone.0049481. Epub 2012 Nov 9.